Therefore, we tested the effects of incubating varying concentrations of the drug (5, 10, and 20 μM) for 3 days on primary CLL PBMCs (n = 7 patients), either unstimulated or CpG-ODN + IL15-stimulated (Fig. 5A, upper and lower panels, respectively; Fig. S10A). Here, IL15 is linked to B-cell chronic lymphocytic leukemia.